In silico prediction of N-nitrosamine degradants in API's that possess a secondary or tertiary amine functional group

asa Limited

Ali MA. Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS

Introduction

N-Nitrosamines in pharmaceutical drug substances and products are regarded as a cohort of concern as they are considered potential human carcinogens (Figure 1)¹. Their levels as impurities is guided by the ICH M7 guidance and has led to recall of marketed drug compounds such as ranitidine and sartan medicines². The industry guidance issued by the FDA (2021 revision) stipulates that a risk assessment of the degradation pathway of a drug product should be considered to assess the risk of nitrosamine impurity formation³ (Scheme 1).

Drug degradation knowledge can be encapsulated within a knowledge base as a collection of transformations, accessible through the *in silico* tool Zeneth⁴. Recently a series of transformations predicting the N-nitrosation of secondary and tertiary amines have been developed. Their general chemical space and mechanism is discussed, together with the environmental conditions under which they are deployed (as a prediction) for a chemically relevant API.



Figure 1: Cytochrome P450-catalysed metabolism of NOCs producing

DNA-damaging intermediates.



Degradation Product: A molecule resulting from a chemical change in the drug molecule brought about over time and/or by the action of light, temperature, pH, water, or by reaction with an excipient and/or the immediate container/closure system.



Scheme 1: International regulatory guidance of a new degradation product (including types of studies to be conducted and characterisation of the degradation products).

Formation of N-nitroso compounds

Nitrites (NO_2) and nitrates (NO_3) can react with secondary and tertiary amines to generate N-nitroso compounds (NOCs)⁵. Many API's contain secondary/tertiary amine functionality and if contaminated with a source of nitrites/nitrates (from excipients or container/packaging) then a nitrosation reaction could take place.

A nitrosating agent is regarded as a nitrosonium ion carrier ([NO⁺]), of electrophilic character, which is prone to



attack nucleophiles such as amino compounds⁶. The most general nitrosating reagent is nitrous acid formed by reaction of a mineral acid, with sodium nitrite in water or in a mixture of water and an organic solvent (Figure 2).

Results and discussion

Figure 2: N-Nitrosation of a secondary amine by [NO+] carrier.

In order to evaluate the chemistry that should be covered by the Zeneth knowledge base, a thorough investigation of the literature was conducted and a total of 8 new transformations have been scoped, covering both secondary and tertiary amines:



Table 1: New transformation classes for secondary and tertiary amines (nitrosation taking place with nitrous acid under acidic conditions).

Conclusions

In total, eight transformations have been developed and are currently under review to be incorporated into the Zeneth knowledge base. Generally, tertiary amines are much less reactive than secondary amines because they require an additional dealkylation step (Table 1); the α -CH bond breakage deemed to be the rate determining step. Hence these will have a lower likelihood score in Zeneth. The addition of this chemistry now allows Zeneth to predict the formation of NOCs observed for compounds such as norfloxacin, ranitidine, doxylamine and metformin, when the presence of nitrite/nitrous acid is indicated.

References

- 1. Carlson ES, Upadhyaya P, Hecht SS. A General Method for Detecting Nitrosamide Formation in the In Vitro Metabolism of Nitrosamines by Cytochrome P450s. J. Vis. Exp. (127), e56312.
- 2. ICH Guideline M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. 2014. https://www.ema.europa.eu/en/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential. 3. U.S. Food and Drug Administration (FDA). Information about Nitrosamine Impurities in Medications. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications.
- 4. Kleinman MH, Baertschi SW, Alsante KM, Reid DL, Mowery MD, Shimanovich R, Foti C, Smith WK, Reynolds DW, Nefliu M, Ott MA. In silico prediction of pharmaceutical degradation pathways: A benchmarking study. Mol. Pharmaceut. 2014, 11, 4179-4188.
- 5. Lopez-Rodríguez R, McManus JA, Murphy NS, Ott MA and Burns MJ. Pathways for N-nitroso compound formation: secondary amines and beyond. Org. Process. Res. Dev. 2020, 24, 1558–1585.
- 6. Williams DLH. Nitrosation Reactions and the Chemistry of Nitric Oxide; Elsevier: Amsterdam, 2004.
- 7. Loeppky RN, Outram JR, Tomasik W, Faulconer JM. Rapid Nitrosamine Formation from a Tertiary Amine: The Nitrosation of 2-(N,N-Dimethylaminomethyl)Pyrrole. Tetrahedron Lett. 1983, 24, 4271–4274.

shared **knowledge** • shared **progress**